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Abstract
Background: Many patients present to dental clinics for treatment of painful conditions. Prior to
seeking treatment, many of these patients will self-medicate with non-prescription analgesics
(NPA), and some will unintentionally overdose on these products. The objective of this study is to
describe the use of NPA among dental patients.
Methods: All adult patients presenting to an urban dental clinic during a two-week period in
January and February of 2001 were approached to participate in this research project. Trained
research assistants using a standardized questionnaire interviewed patients. Patient demographics
and the NPA usage over the 3 days preceding the office visit were recorded. We defined a supra-
therapeutic dose as any dose greater than the total recommended daily dose stated on package
labeling.
Results: We approached 194 patients and 127 participated. The mean age of participants was 35.5
years, 52% were male. Analgesic use preceding the visit was reported by 99 of 127 patients, and
most (81/99) used a NPA exclusively. Fifty-four percent of NPA users were taking more than one
NPA. NPA users reported using ibuprofen (37%), acetaminophen (27%), acetaminophen/aspirin
combination product (8%), naproxen (8%), and aspirin (4%). Sixteen patients reported supra-
therapeutic use of one or more NPA (some ingested multiple products): ibuprofen (14),
acetaminophen (3), and naproxen (5).
Conclusion: NPA use was common in patients presenting to a dental clinic. A significant minority
of patients reported excessive dosing of NPA. Ibuprofen was the most frequently misused product,
followed by naproxen and acetaminophen. Though mostly aware of the potential toxicity of NPA,
many patients used supra-therapeutic dosages.
Background
Pain is a common complaint among patients presenting
for emergency care at a dental clinic. Non-prescription
analgesic pain relievers are commonly used by patients
with dental pain. They decrease pain when administered
after dental extractions [1-3] and when administered prior
to dental surgery [4]. There are fewer studies evaluating
the utility of these products for dental pain not related to
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dental procedures. Korberly studied patients presenting to
a dental clinic for acute pain and found that both acetami-
nophen (1 g) and aspirin (1 g) decreased pain relative to
placebo.[5] These studies all suggest that non-prescription
analgesics are an effective therapy for dental pain.
When the manufacturer's recommended dosing is fol-
lowed, these medications are very safe. Still, two recent
reports have highlighted the risk of accidental acetami-
nophen overdose during treatment of dental pain[6,7]
Patients with occult acetaminophen overdose may
present dramatically with acute liver failure, and there are
risks from over use of non-steroidal anti-inflammatory
drugs (NSAIDS). While doses of ibuprofen under 1200
mg/day minimally increase the risk of gastrointestinal
(GI) bleeding (relative risk 1.1 vs no medication), the pre-
scription dose increases the risk of bleeding dramatically
(relative risk of 4 vs no medication).[8] The risk is higher
with prolonged use, but one study has reported patients
starting naproxen are at higher risk than those starting
ibuprofen and that that difference is detectable within 14
days.[9] This suggests that even a few days of use results in
increased potential for injury. As some estimate that up to
15,000 people die per year in the United States as a com-
plication of their NSAID treatment [10], NSAID overuse is
a potential major health issue.
Given the severity of dental pain and the difficulty that
many patients have accessing dental care, we believe that
patients presenting to a dental clinic may represent a
group at high risk of unintentional overdose. The purpose
of this study was to characterize the use of non-prescrip-
tion analgesics by patients at an urban dental health
clinic.
Methods
All adult patients presenting to an urban dental clinic pro-
vided at a safety net hospital during a two-week period
were approached to participate in the research project.
This study was conducted in January and February of
2001. Patients of either gender, 18 years of age or greater
were included if they provided informed consent. We
excluded patients who did not speak English or who were
unwilling or unable to provide informed consent. The
local Institutional Review Board approved this study.
The clinic is open from 08:00 to 17:00 with resident cov-
erage overnight and provides care for 17,000 patient
encounters per year. The primary patient complaint at
these encounters is dental pain. Trained research assist-
ants using a structured questionnaire approached all
patients in the clinic. During the survey, patients were
asked to name which non-prescription analgesic products
they had used (including doses) on the day of the visit and
in the 2 days preceding their visit. A book of photographs
displaying the packaging for the 22 most popular analge-
sic products was used as a prompt when needed. Patients
who gave a history of supra-therapeutic use of a non-pre-
scription analgesic were given a printed sheet advising
them to seek medical advice in case they experienced
abdominal pain, nausea, vomiting, or yellowing of the
skin. No attempt was made to assess the patient for signs
of toxicity.
After the data collection was complete, responses were
tabulated and entered into Microsoft Access. When the
patient provided a specific dose, this dose was accepted
and entered as the dose. When a patient did not know the
dose, the interviewer attempted to obtain an exact product
name and the amount taken. When an exact product
name was provided, the dose of each medication in the
product was determined from a standard database (Micro-
medex®, Englewood CO), if the patient could recall the
number of pills ingested. If an exact product could not be
determined, the lowest dose formulation of the medica-
tion available was used to determine the dose ingested by
the patient. The maximum daily non-prescription doses
were determined from the manufacturer's label and are
shown in Table 1. Patients reported daily doses in excess
of these values were counted as overusers. Proportions
and percentages (with 95% confidence intervals) were
reported for all responses. Relative risks with 95% confi-
dence intervals were used to compare sex, age group and
type of analgesic used between overusers and non-overus-
ers.
Results
We approached 194 patients, of which 127 participated.
Of the 67 patients who did not participate, 37 were not
interested or in too much pain to participate and 30 did
not speak English. The participants had a mean age of
35.5 years (range 18 to 68 years) and had a slight male
predominance (52%). Non-participants were of similar
age and gender. Overall, 99/127 (78%; 95% confidence
interval [CI] 70 to 84%) patients reported using an anal-
gesic. Eighteen (14%; CI 8 to 21%) patients were taking a
prescription analgesic only, 37 (29%; CI 21 to 38%) were
taking a single non-prescription analgesic. Twenty-nine
Table 1: Maximum daily non prescription and prescription doses 
for acetaminophen, aspirin, ibuprofen and naproxen
Medication Non-prescription Prescription
Acetaminophen 4000 mg 4000 mg
Aspirin 3900 mg 3900 mg1
Ibuprofen 1200 mg 2400 mg
Naproxen sodium2 660 mg 1100 mg
1. For rheumatoid arthritis the dose may be increased to achieve a 
serum concentration of 30 mg/dl.
2. To convert to naproxen decrease the dose by 10%.BMC Oral Health 2008, 8:33 http://www.biomedcentral.com/1472-6831/8/33
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(23%; CI 15 to 21%) patients were taking two medica-
tions, 12 (9%; CI 5 to 16%) patients were taking three
medications, and 3 (2%) patients were taking 4 medica-
tions.
Acetaminophen, as an non-prescription preparation, was
used by 34/127 patients (27%; CI 19 to 35%), non-pre-
scription ibuprofen was used by 47 patients (37%; CI 28
to 46%), acetaminophen/aspirin combination products
were used by 10 patients (8%; CI 3 to14%), non-prescrip-
tion naproxen was used by 10 patients (8%; CI 3 to 14%),
and aspirin was used by 6 patients (4%; CI 2 to 10%).
Twenty-six patients (26%; 18 to 36%) were taking a pre-
scription medication that contained acetaminophen as an
ingredient in addition to at least on non-prescription
analgesic, including 3 who took non-prescription aceta-
minophen.
Sixteen percent of non-prescription analgesic users
reported exceeding the manufacturer’s recommended
daily dosage. The median doses, interquartile ranges and
ranges for patients who reported exceeding the recom-
mended dose is shown in table 2. The incidence of over-
use for each medication was ibuprofen 14/47 (23%; CI 12
to 38%); acetaminophen 3/34 (12%; CI 3 to 27%); and
naproxen 5/10 (50%; CI 19 to 81%). Thirteen patients
exceeded the recommended dose for a single non-pre-
scription analgesic (4 naproxen and 9 ibuprofen), while
three reported exceeding the recommended dose for ibu-
profen and acetaminophen and one exceeded the recom-
mended dose for ibuprofen, acetaminophen and
naproxen. No patient exceeded the recommended dose of
aspirin or of acetaminophen/aspirin combination prod-
ucts. Three patients were taking acetaminophen in addi-
tion to a prescription combination analgesic medication
containing acetaminophen. As we only gathered dose data
on non-prescription analgesic, we could not determine if
the combined total acetaminophen dose of the non-pre-
scription analgesic product and prescription product
exceeded the maximum recommended dose of acetami-
nophen in these three patients.
The risk of overuse by men was 1.3 the risk for women
(95% CI 0.5 to 3.3). The rate of overdose for patients age
<30 years, 31–50 years, and >50 years were 5/50 (10%; 3
to 22%), 11/59 (19%; 10 to 31%) and 0/17 (0; 0 to 19%)
respectively. These rates were not significantly different.
Ibuprofen and naproxen users were more likely [RR = 1.6
(95% CI 0.55 to 4.9) and 4.2 (95% CI 1.4 to 12.9) respec-
tively] to overuse than acetaminophen users.
Discussion
The vast majority of dental clinic patients interviewed
were using a product containing a non-prescription anal-
gesic. The pattern of non-prescription analgesic use has
been changing as newer products become available. Stud-
ies in the 1970s reported that dental clinic patients prima-
rily used aspirin [11], while studies in the 1980s reported
a majority of patients using acetaminophen [12]. It now
appears that ibuprofen is the medication of choice for the
majority of patients, although acetaminophen remains a
common choice. This is similar to the medication selec-
tion pattern reported for emergency department patients
[13].
A substantial minority of patients exceeded the maximum
daily dosage recommended by the manufacturer. The rate
of overuse is similar to the rate reported by Preshaw 25
years ago. In that study, 7.6% of patients in a British den-
tal practice reported excessive dosing [14]. This suggests
that the issues that lead to misuse have existed for many
years.
The reason for overuse cannot be determined from the
present study design. We suspect it is multi-factorial. One
issue is the inadequate use of preventative dental care that
allows caries to progress to the point where they invade
the pulp and cause pain. This may be due to cost, lack of
an available provider or patient apathy. Regardless, these
issues are beyond the scope of our research. Once pain
occurs, patients may become desperate and can resort to
extreme measures to obtain relief. One way patients seek
relief is by taking prescription medications (obtained
from old prescriptions, friends or purchased on the black
market). This may have several health implications. We
did not attempt to quantify acetaminophen use in pre-
scription products, but accidental acetaminophen over-
dose due to overuse of acetaminophen/opioid
combination products is well described.[15] Simultane-
ous ingestion of prescription and nonprescription aceta-
minophen products is another cause of inadvertent
overdose. We identified several cases of simultaneous pre-
scription and non-prescription use, suggesting that this is
Table 2: Maximum daily dose (mg) for patients who exceeded the recommended non-prescription dose of analgesics.
Medication N Median Interquartile range Range
Acetaminophen 3 6000 5000–9000 5000–9000
Ibuprofen 14 1600 1600–3500 1600–12000
Naproxen sodium 5 880 880–2035 880–2200BMC Oral Health 2008, 8:33 http://www.biomedcentral.com/1472-6831/8/33
Page 4 of 5
(page number not for citation purposes)
a fairly common event. Further work is required to better
characterize this issue.
The frequent overuse of non-prescription analgesics has
several safety implications. These medications are safe
when used in recommended doses. However, the adverse
effects of these medications are clearly dose-related, and
our data suggest that patients are exceeding the recom-
mended doses. The continued non-prescription availabil-
ity of these medications requires that the risk/benefit
analysis consider some patients will not use these medica-
tions as directed, and therefore be subject to risk above
those associated with non-prescription dosing for
NSAIDS and will also result in patients who develop liver
injury or failure from accidental acetaminophen over-
dose.
The second implication is that patients lack adequate edu-
cation regarding the appropriate use of non-prescription
analgesics. Cham et al, conducted a survey with patients
presenting to an emergency department to determine the
prevalence of non-prescription analgesic use and measure
patient knowledge about the potential adverse effects of
misuse of these products. This study found an incidence
of non-prescription analgesic use similar to the one
reported in our study (67%; 143/213 reported NSAID use
and 60%; 127/213 reported use of acetaminophen).
Cham also found that many, 64% of the patients sur-
veyed, were ill informed about the potential adverse
effects from misuse of non-prescription analgesic prepara-
tions [16]. One plausible explanation for these findings is
that while patients have a general idea that "too much is
bad", they do not know the appropriate doses of these
medications and the specific adverse reactions that occur
when these doses are exceeded. If this explanation is cor-
rect, then there is a need for improved patient education.
Healthcare providers have a clear opportunity for inter-
vention. Ideally, this intervention would be education
and prevention. Counseling patients on appropriate treat-
ment of dental pain could be a part of routine dental care.
However, as many patients do not present to dental care
until symptoms have developed, there may be no oppor-
tunity for prevention in many cases. In these cases, it is
important that dentists ascertain the extent of non-pre-
scription analgesics use to identify patients who have
taken potentially dangerous doses of these medications.
Once these patients are identified, the provider should
provide education about appropriate non-prescription
analgesic use, and possibly refer these patients for evalua-
tion for occult toxicity from these drugs.
Limitations
These results indicate there is potential for supra-thera-
peutic dosing in patients who are experiencing dental
pain. However, the results of this survey are from a small
sampling of dental patients and only over a 2-month
timeframe. In addition, patient recall of non-prescription
analgesic use over the past 72 hours may have been
incomplete or inaccurate. We attempted to improve prod-
uct identification by providing patients with a book of
photographs with the 22 most popular analgesics to help
recall the type of medication used. There may have been
other sources of acetaminophen or non-steroidal anti-
inflammatory medications in cold and cough prepara-
tions, for example. Our study did not measure the dura-
tion of use, which can also alter the risk for toxicity.
Finally, we only measured the prevalence of overuse and
did not determine if any patients had injury from overuse.
Conclusion
Non-prescription analgesic use is common in patients
presenting to a safety net dental clinic, and a significant
minority of these patients overuse these products. Nons-
teroidal anti-inflammatory drugs are the most frequently
misused products, but patients also overuse acetami-
nophen. This overuse may place patients at increased risk
for adverse events from these products.
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